Highly Specific Assays
Detecting nucleic acids and proteins have been is made possible by the historic and revolutionary technologies like Polymerase Chain Reaction (PCR) and ELISA. PCR currently cannot be applied to non-nucleic biomolecules and ELISA has limited sensitivity. Immuno-PCR is another powerful technology that combines PCR and ELISA. This technology is an advancement over the immuno-PCR detection technique using DNA- Avidin in reporter nanoparticles. The multi template DNA-Avidin nanoparticles created have specific sensitivity to multiple biotin binding sites. The assay results in 100X more sensitivity compared to currently used immuno-assays.
Applications
  • Detection of specific non-nucleic biomolecules including hormones, biomarkers, toxins etc.
Problems Addressed
  • PCR is a highly sensitive assay, however it only works in the presence of nucleic acids
  • ELISA is applicable for hormone, antibodies, proteins toxins, however has lower sensitivity than PCR
  • Immuno-PCR combines the specificity of an ELISA with the signal amplification of PCR. However, its sensitivity is not adequate for the detection of analytes of low abundance
  • Immuno-PCR is a complex and expensive assay
Competitive Advantages
  • Highly sensitive and applicable to multiple biomolecules
  • Avoids antibody-DNA conjugation
  • Assay does not require fresh tissue biopsy
Patents
  • Provisional patent filed
Case ID
2016-051
Inventor
Dr. Richard Willson
Huffington-Woestemeyer Professor of Biochemical & Biophysical Sciences
Category